Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
Takeda Pharmaceutical notched up double-digit profit growth in the year ended in March on group revenues of 1.77 trillion yen, which rose 2.2% over the previous year as bullish Entyvio (vedolizumab) sales more than offset a decline stemming from the…
To read the full story
Related Article
- Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
May 15, 2019
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…